ASCO® 2024 Insights: "KIM-1 Biomarker Analysis in IMmotion010 - Adjuvant Atezo vs. Placebo in RCC Patients at Increased Risk of Recurrence After Resection"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KIM-1 Biomarker Analysis in IMmotion010 - Adjuvant Atezo vs. Placebo in RCC Patients at Increased Risk of Recurrence After Resection"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Laurence Albiges

64 views

June 7, 2024

Chapters

Introduction to KIM-1 & IMmotion010 Study

00:00

Biomarker Identification & KIM-1 Significance

01:37

KIM-1 Levels & Disease-Free Survival Outcome

05:16

Atezolizumab Treatment & KIM-1 Predictive Value

06:46

Conclusions & Future Directions for KIM-1

07:50

Comments 0

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

2024 ASCO® Annual Meeting Insights Hub: GU Videos

ASCO® 2024 Insights: "Landscape Analysis & Oncologic Outcomes in Adv…

2024 ASCO® Annual Meeting Insights Hub

T. Stewart

11 views

1 month ago

ASCO® 2024 Prostate Cancer Take-Home Messages

2024 ASCO® Annual Meeting Insights Hub

E. Efstathiou

606 views

3 months ago

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

364 views

4 months ago

View All

APCCC 2026

Fri, Feb 27, 2026

RENALC-BLADDR-PROSCA 2024

RENALC 2024 - Hybrid Global Forum on GU Oncology

Tue, Nov 26, 2024

See 1 other

RENALC-BLADDR-PROSCA 2024

PROSCA 2024 - Hybrid Global Forum on GU Oncology

Thu, Nov 28, 2024

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

2.6K views

9 months ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

5 months ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

432 views

1 month ago

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Robert Dreicer

1.3K views

11 months ago

Testosterone Suppression and Recovery in Patients With Advanced Pros…

Benjamin L. Maughan

661 views

5 months ago

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

SIR 2023 Conference Coverage

N. Kothary

3.0K views

1 year ago

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

276 views

1 month ago

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

529 views

8 months ago

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

2024 ASCO® Annual Meeting Insights Hub

K. Mittal

364 views

4 months ago

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

2024 ASCO® Annual Meeting Insights Hub

J. Hafron

643 views

5 months ago

Opus One: Final Results - RFA in Axial Skeleton

Jason Levy

2.0K views

1 year ago

New

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

178 views

2 weeks ago

New

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

Penn Medicine Abramson Cancer Center

D. Lee

194 views

1 week ago

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

236 views

3 weeks ago

Urothelial Carcinoma: New Developments

Weill Cornell Medicine Oncology & Hematology

C. Sternberg

344 views

5 months ago

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

University of Colorado Cancer Center

T. Flaig

337 views

6 months ago

ASCO® 2024 Summary: "Bladder and RCC Highlights"

2024 ASCO® Annual Meeting Insights Hub

K. Tawagi, N. Reizine

263 views

4 months ago

AUTOPLAY

Login

Login

Join VuMedi

ASCO® 2024 Insights: "KIM-1 Biomarker Analysis in IMmotion010 - Adjuvant Atezo vs. Placebo in RCC Patients at Increased Risk of Recurrence After Resection"

Introduction to KIM-1 & IMmotion010 Study

Biomarker Identification & KIM-1 Significance

KIM-1 Levels & Disease-Free Survival Outcome

Atezolizumab Treatment & KIM-1 Predictive Value

Conclusions & Future Directions for KIM-1

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

2024 ASCO® Annual Meeting Insights Hub: GU Videos

ASCO® 2024 Insights: "Landscape Analysis & Oncologic Outcomes in Adv…

ASCO® 2024 Prostate Cancer Take-Home Messages

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

Recommended

APCCC 2026

RENALC 2024 - Hybrid Global Forum on GU Oncology

PROSCA 2024 - Hybrid Global Forum on GU Oncology

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Recent GU Developments and Their Clinical Implications

Bladder Cancer Highlights From ASCO® 2024

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Hyperprogression in Cancer Treated With Immunotherapy

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Testosterone Suppression and Recovery in Patients With Advanced Pros…

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

ASCO® 2024 Summary: "Current Updates in RCC - Clinical Implications …

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

Opus One: Final Results - RFA in Axial Skeleton

Visible vs. Invisible Cancers - The Genomics and Natural History

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

ESMO 2024 Summary: Developmental Therapeutics Highlights

Urothelial Carcinoma: New Developments

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

ASCO® 2024 Summary: "Bladder and RCC Highlights"